161 related articles for article (PubMed ID: 25092564)
1. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Geng C; Hou J; Zhao Y; Ke X; Wang Z; Qiu L; Xi H; Wang F; Wei N; Liu Y; Yang S; Wei P; Zheng X; Huang Z; Zhu B; Chen WM
Am J Hematol; 2014 Nov; 89(11):1037-42. PubMed ID: 25092564
[TBL] [Abstract][Full Text] [Related]
2. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.
Leng Y; Qiu L; Hou J; Zhao Y; Zhang X; Yang S; Xi H; Huang Z; Pan L; Chen W
Chin J Cancer; 2016 Sep; 35(1):86. PubMed ID: 27608772
[TBL] [Abstract][Full Text] [Related]
3. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.
Leng Y; Hou J; Jin J; Zhang M; Ke X; Jiang B; Pan L; Yang L; Zhou F; Wang J; Wang Z; Liu L; Li W; Shen Z; Qiu L; Chang N; Li J; Liu J; Pang H; Meng H; Wei P; Jiang H; Liu Y; Zheng X; Yang S; Chen W
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1141-1149. PubMed ID: 28500554
[TBL] [Abstract][Full Text] [Related]
4. A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma.
Hou J; Qiu L; Zhao Y; Zhang X; Liu Y; Wang Z; Zhou F; Leng Y; Yang S; Xi H; Wang F; Zhu B; Chen W; Wei P; Zheng X
Am J Clin Oncol; 2018 Oct; 41(10):1008-1014. PubMed ID: 28930776
[TBL] [Abstract][Full Text] [Related]
5. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
Xia Z; Leng Y; Fang B; Liang Y; Li W; Fu C; Yang L; Ke X; Jiang H; Weng J; Liu L; Zhao Y; Zhang X; Huang Z; Liu A; Shi Q; Gao Y; Chen X; Pan L; Cai Z; Wang Z; Wang Y; Fan Y; Hou M; Ma Y; Hu J; Liu J; Zhou J; Zhang X; Meng H; Lu X; Li F; Ren H; Huang B; Shao Z; Zhou H; Hu Y; Yang S; Zheng X; Wei P; Pang H; Yu W; Liu Y; Gao S; Yan L; Ma Y; Jing H; Du J; Ling W; Zhang J; Sui W; Wang F; Li X; Chen W
BMC Cancer; 2023 Oct; 23(1):980. PubMed ID: 37838670
[TBL] [Abstract][Full Text] [Related]
6. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
Kodama T; Abe M; Iida S; Ozaki S; Sakai A; Sawamura M; Shimazaki C; Miyata A; Wakayama T; Murakami H
Clin Lymphoma Myeloma; 2009 Apr; 9(2):154-9. PubMed ID: 19406727
[TBL] [Abstract][Full Text] [Related]
8. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
[TBL] [Abstract][Full Text] [Related]
10. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
Palumbo A; Larocca A; Genuardi M; Kotwica K; Gay F; Rossi D; Benevolo G; Magarotto V; Cavallo F; Bringhen S; Rus C; Masini L; Iacobelli M; Gaidano G; Mitsiades C; Anderson K; Boccadoro M; Richardson P;
Haematologica; 2010 Jul; 95(7):1144-9. PubMed ID: 20053869
[TBL] [Abstract][Full Text] [Related]
11. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
16. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Suvannasankha A; Fausel C; Juliar BE; Yiannoutsos CT; Fisher WB; Ansari RH; Wood LL; Smith GG; Cripe LD; Abonour R
Oncologist; 2007 Jan; 12(1):99-106. PubMed ID: 17227904
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma.
Chiou TJ; Wang TH; Chao TY; Lin SF; Tang JL; Chen TY; Chang MC; Hsueh EJ; Chen PM
Cancer Invest; 2007; 25(3):140-7. PubMed ID: 17530483
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2
Mey UJ; Brugger W; Schwarb H; Pederiva S; Schwarzer A; Dechow T; Jehner P; Rauh J; Taverna CJ; Schmid M; Schmidt-Hieber M; Doerfel S; Fischer N; Ruefer A; Ziske C; Knauf W; Cathomas R; von Moos R; Hitz F; Sauter R; Hiendlmeyer E; Cantoni N; Bargetzi M; Driessen C
Br J Haematol; 2017 Mar; 176(5):770-782. PubMed ID: 27983764
[TBL] [Abstract][Full Text] [Related]
19. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
[TBL] [Abstract][Full Text] [Related]
20. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Murakami H; Handa H; Abe M; Iida S; Ishii A; Ishikawa T; Ishida T; Oota M; Ozaki S; Kosaka M; Sakai A; Sawamura M; Shimazaki C; Shimizu K; Takagi T; Hata H; Fukuhara T; Fujii H; Miyata A; Wakayama T; Takatsuki K
Eur J Haematol; 2007 Sep; 79(3):234-9. PubMed ID: 17655699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
